secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERU INC. (VERU)
CIK:        0000863894
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001193125-24-196459
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veru Q3 net rev $4.0M, net loss $0.07; Phase 2b QUALITY study fully enrolled (>150 pts), topline Jan 2025
--------------------------------------------------------------------------------

- Q3 net revenue $4.0M (up 21% YoY); operating loss $10.9M vs $13.7M.
- Net loss $11.0M ($0.07/sh) vs $12.5M ($0.14/sh) prior year.
- Phase 2b QUALITY trial full enrollment >150 patients achieved; topline lean body mass data expected Jan 2025.
- Cash $29.2M at June 30, 2024 vs $9.6M at Sept 30, 2023.
- Enobosarm aims to preserve muscle during GLP-1 weight loss; extension study data expected Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/0001193125-24-196459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/863894/000119312524196459/d877606d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-196459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer